Last Updated: August 22, 2026

Details for Patent: 12,295,988


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,295,988 protect, and when does it expire?

Patent 12,295,988 protects OZEMPIC and is included in one NDA.

This patent has thirty-two patent family members in eighteen countries.

Summary for Patent: 12,295,988
Title:Semaglutide in medical therapy
Abstract:The present invention relates to semaglutide for use in weight management.
Inventor(s):Lars Holm Damgaard, Soeren Oestergaard Hardt-Lindberg, Thomas Hansen
Assignee: Novo Nordisk AS
Application Number:US18/820,792
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 12,295,988
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 12,295,988

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-007 May 5, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING TYPE 2 DIABETES ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-004 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING TYPE 2 DIABETES ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-002 Apr 9, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING TYPE 2 DIABETES ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-003 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING TYPE 2 DIABETES MELLITUS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,295,988

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018348929 ⤷  Start Trial
Australia 2025203535 ⤷  Start Trial
Brazil 112020006246 ⤷  Start Trial
Canada 3078652 ⤷  Start Trial
Chile 2020000812 ⤷  Start Trial
China 111212657 ⤷  Start Trial
China 119838000 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.